 |
|
 Home |
 |
| Overview |
|
| Videos |
|
| Background |
|
| The Science |
|
| Contact Us |
|
| Replikins Press |
|
 |
|
|
The Science The x axis of Figure 3 indicates the year and the y axis indicates the Replikin Count™ peptide quantities per 100 amino acids. The appearance of the SARS outbreak and the number of countries involved is shown by the vertical dotted columns. The solid black symbols represent the mean Replikin Count™ peptide quantities for spike coronavirus proteins and the vertical black bars represent the standard deviation of the mean. Figure 3 shows a remarkable constancy of low coronavirus Replikin Count™ peptide quantities between 1994 and 2001 in the spike proteins, followed by a dramatic increase in 2002, one year before the SARS epidemic appeared in 2003. Figure 2 shows that whereas the Replikin Count™ peptide quantities of the spike proteins in SARS returned to their normal pre-2003 levels (correlated with the disappearance of SARS), the Replikin Count™ peptide quantities™ peptide quantity of H5N1 Bird Flu has not returned to normal (Please note that there is a possible increase in coronavirus Replikin Count™ peptide quantities in the first quarter of 2006 (not shown in Figure)). The above Figures show both the predictive and the tracking value of the company's FluForecast™ product. The methods of the FluForecast™ product are also applicable to other infectious groups, including but not limited to Malaria, HIV, foot and mouth disease, and aquatic and plant disease. The company knows of no other products which quantitatively predict or track epidemics. 1 2 3 4 5 |
| Recent Press | |
Boston, November 27, 2009 - Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus... |
|
| New Non-Biological Synthetic Replikins™ Vaccines Shown to Be Effective and Fast; WorldVaccines™, Ltd. Formed for Testing and Distribution Old Biological Vaccines for Emergent Diseases - Too Little, Too Late
Boston, October 19, 2009 - There is increasing evidence that, with best intent, current biological technology cannot supply the world's six billion humans, and animal populations, with vaccines against emerging diseases at a rate that can contend with a disease's rapid appearance and change... |
|
Copyright © 2010 Replikins Ltd. All rights reserved.